Today: 28 February 2026
Subscribe
Browse Category

NYSE:DGX 29 July 2025 - 4 December 2025

Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers shares jumped about 8% Thursday to $40.19 after announcing a Canada launch, backed by its Livewell acquisition. The company also agreed to buy YourBio Health and recently launched a diagnostics platform with Quest Diagnostics. Market cap stands near $12.8 billion. Short interest remains high, with 67.6 million shares sold short, or about 36% of the float.
4 December 2025
···
Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health shares fell about 7–8% to $36.05 Friday after launching its new Labs diagnostic platform with Quest Diagnostics. The company’s market cap stands near $8.2 billion. Labs offers nationwide blood testing and health monitoring through annual subscriptions. The stock remains up roughly 43% year-to-date but trades well below its 52-week high.
14 November 2025
··
AI Just Diagnosed You—Now What? The Rise of Superhuman Doctors Made of Code

AI Just Diagnosed You—Now What? The Rise of Superhuman Doctors Made of Code

An AI chatbot diagnosed a U.S. boy’s chronic pain as spina bifida occulta after 17 doctors failed; a specialist confirmed the result. Microsoft’s MAI-DxO correctly diagnosed 85% of nearly 300 complex cases, far surpassing physicians. By October 2024, the FDA had cleared over 1,000 AI medical devices, mainly for radiology, but no generative AI system had full approval as a medical device.
29 July 2025
····
Go toTop